Thursday, September 15, 2016 5:29:22 PM
Nutra Pharma's MS drug is real. The fact that the FDA granted them an Orphan Designation is real. I got excited when they announced Dale Vanderputten joining the company - - because he's real.
Sales would be phenomenal and would certainly increase PPS - but any real value would have to be in the speculation of an eventual blockbuster drug (i.e. MS, RA, etc..). I could even argue that sales de-value a Biotech company because it gives investors something to tack value to instead of the exciting nature of a future drug.
So - let's see some sales, but if these guys can get a Phase II started in MS we could really something.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM